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Background
The World Bank ranks soil-transmitted
helminth infection as causing more ill health
in children aged 5–15 years than any other
infection. In light of this ranking, global
agencies recommend regular, mass treat-
ment with deworming drugs to children in
developing countries [1,2]. The World
Health Organization (WHO) argues that
‘‘deworming helps meet the Millennium
Development Goals’’ [3], in particular the
six health-related goals: (1) eradicate ex-
treme poverty and hunger; (2) achieve
universal primary education; (3) promote
gender equality and empower women; (4
and 5) reduce child mortality and improve
maternal health; and (6) combat HIV/
AIDS, malaria, and other diseases (http://
www.un.org/millenniumgoals). However,
deworming campaigns cost money to deliv-
er, and so we must be clear that WHO
statements about the impact of these
programmes are based on reliable evidence.
In 2000, we systematically reviewed the
reliable evidence from relevant controlled
trials about the effects of anthelminth
drugs for soil-transmitted helminth infec-
tion on child growth and cognition [4].
This systematic review, published in The
Cochrane Database and the BMJ [4,5],
demonstrated uncertainty around the as-
sumed benefit and concluded that it may
be a potentially important intervention,
but needed better evaluation.
The BMJ published a large number of
letters that criticised the findings, including
from authors at the World Bank, the
WHO, the United States Centers for
Disease Control and Prevention, and the
Pan American Health Organization [6].
We do not feel that these criticisms were
scientifically substantive enough to under-
mine the method or the conclusion (see
‘‘Authors’ reply’’ in [6]). For example,
several critics commented on the fact that
the systematic review could not make any
conclusions about the long-term effects of
treatment—but, as we argued in our reply
to these criticisms, ‘‘we were unable to find
any randomised controlled trials that
evaluated long term benefit, and the
evidence of short term benefit was not,
for us, convincing.’’ The research com-
munity quite correctly carried out further
randomised controlled trials (RCTs) of
repeated doses in community trials with
longer follow-up compared with no inter-
vention or placebo. In light of this
additional research, we have now updated
the original Cochrane review [7]. An
author of one of the trials included in the
2000 review, Ed Cooper, criticised the
review for not taking into account hetero-
geneity in parasite burdens [8]. Therefore,
in the recently updated review, we con-
ducted an additional subgroup analysis at
trial level stratified by worm intensity and
prevalence [7].
Updated Cochrane Review
Our objectives were to summarize the
effects of deworming drugs used to treat
soil-transmitted intestinal worms on two
outcomes: growth and school performance
in children. The inclusion criteria were
RCTs and quasi-randomised controlled
trials that evaluated these outcomes. A
total of 34 trials were included, including
ten new trials since the 2000 review. Six
trials in the 2000 review were excluded
from the updated systematic review, as our
methods of applying inclusion criteria
have become more exacting [7]—for
instance, trials with only two units of
allocation, and trials that ignored rando-
misation in the analysis were excluded in
the updated review.
Of the ten new trials, three were cluster
randomised ([9,10] and A. Hall, B.
Nguyen, D. Bundy, D. Quan, S. Hong,
et al. unpublished data). This design helps
capture the potential positive impact of
treating a whole community by reducing
transmission. One unpublished trial from
Vietnam, with 2 years follow-up, kindly
provided by the authors, did not demon-
strate a significant difference in weight
gain. Clustering was not taken into
account in the analysis, which artificially
narrows the confidence intervals, but even
with appropriate correction the result will
remain non-significant (A. Hall, B.
Nguyen, D. Bundy, D. Quan, S. Hong,
et al. unpublished data). A second trial
over 3 years, involving 27,995 children,
also did not take clustering into account
[9]. This second trial, published in the
BMJ, reported a significant effect in
weight gain in the intervention group;
however, the children were randomised
across 50 parishes, and when the authors
kindly at our request adjusted the data for
clustering, the data showed no significant
difference between the intervention and
control group (mean and 95% confidence
interval of the difference in weight gain
between the intervention and control
group: 154 g, 219 g to 330 g) (H. Alder-
man, personal communication). The third
trial, by Awasthi and colleagues, did
correct for clustering, and no significant
effect on weight gain was demonstrated in
outcomes measured at 18 months of
follow-up [10].
For trials where data were in a com-
binable form, the evidence has changed a
little (Table S1). Weight gain after one
dose of anthelminth drugs became just
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significant, and with confidence intervals
that include potentially important weight
gain values (Figure S1: WMD 0.34 kg,
95% CI 0.05 to 0.64). However, the effect
was very different between studies, with
large effects in small studies carried out
prior to 1995 [7]. Whilst this effect was
detected in trials in high prevalence areas,
stratification of trials by worm intensity did
not explain the heterogeneity, which was
also present in many of the other analyses.
With multiple doses and longer term
follow-up, no significant results were found
in trials with data used in the meta-analysis
for measures of changes in weight and
height up to 1 year, and after 1 year [7].
However, an important cluster rando-
mised trial in Zanzibar that adjusted
appropriately demonstrated a difference
in weight and height for multiple dosing
within 1 year [11,12].
Two trials reported school attendance,
three reported development status, and
four reported on cognition tests. Overall,
five of the trials demonstrated no treat-
ment effect, one trial noted an improve-
ment in three out of ten cognitive tests
used, and one trial did not report the
results clearly.
Implications of the Review
Deworming drugs are associated with
increases in weight after a single dose.
Generally, there remains no significant
difference detected in multiple dose trials,
apart from the cluster RCT in schools in
Zanzibar [11,12]; more recent cluster
RCTs looking for an effect on weight gain
have failed to demonstrate a difference.
For school performance, data were very
limited, and no convincing treatment
effect was demonstrated. If benefit is not
shown in RCTs, then it seems benefit is
even less likely in ‘‘real world’’ operational
conditions. A reasonable interpretation of
the newly updated systematic review may
be that deworming drugs used in targeted
community programmes may be effective
in relation to weight gain in the short term
in some circumstances, but not in others;
the potential long-term impact has not
been demonstrated conclusively.
Comment
With obvious relationships between
worm infection, health status, and poverty,
randomised trials help differentiate causal-
ity from confounding. Gulani and col-
leagues’ systematic review of intestinal
anthelmintic drugs on anaemia shows a
marginal impact on haemoglobin, and the
authors say that this could translate into a
small effect on anaemia in populations
where worms are common [13]. Our
updated systematic review shows improve-
ments in weight after one dose of de-
worming, but generally not in trials with
longer follow-up, and no evidence of effect
on school performance. Thus, there is a
mismatch between the state of reliable,
direct evidence of benefit and the benefit
claimed by advocates of deworming.
One of the issues with current policies is
that there seems to be conflation of the
diseases in terms of claims of benefit.
Deworming advocates describe the bene-
fits of treating all helminths, including
schistomiasis, filariasis, and soil-transmit-
ted helminths [14]. Thus, evidence for the
benefit of treating populations with schis-
tosomiasis is fairly clear [15], as the
infection has a very substantive effect on
health. There is little debate that treat-
ment helps people with this condition, but
this does not mean a different drug
treating a different helminth is equally
effective.
Another problem in deworming trials
arises when the results may be coun-
founded by concurrent use of deworming
agents for multiple diseases. For example,
one of the problems in interpreting a study
by Miguel and colleagues, where albenda-
zole was used in a quasi-randomised
design, is that praziquantel was used in
some but not other villages, with unknown
confounding effects [16]. This study did
not therefore meet the inclusion criteria in
our updated systematic review, as dis-
cussed in [7].
We believe that evidence-informed pol-
icy needs to be underpinned by specific
reviews that ensure that the interventions
are effective in reducing morbidity or
mortality for the conditions for which they
are being given. We suggest that policy
makers clarify that the research evidence
has sometimes demonstrated benefits and
sometimes has not. Guideline developers
and policy makers at global, national, and
local levels should be allowed to consider
the evidence carefully before committing
to investing existing resources in delivering
these programmes. Our interpretation of
the data is that deworming policies applied
to whole populations may possibly have
benefits in some circumstances, but not in
others. The debate remains open, but the
large DEVTA trial (deworming and vita-
min A; http://www.ctsu.ox.ac.uk/projects/
devta), the world’s largest ever RCT, should
clarify if deworming is worthwhile. The trial
includes over a million children randomised
in a cluster design with mortality as the
primary outcome [17].
Supporting Information
Figure S1 Forrest plot of trials measur-
ing change in weight after one dose of
deworming, grouped by worm prevalence
and intensity
Found at: doi:10.1371/journal.pntd.
0000358.s001 (1.33 MB TIF)
Table S1 Change in nutritional status in
trials in children comparing anthelminth
drugs to no specific anthelminth treat-
ment: reported after single dose and
multiple doses
Found at: doi:10.1371/journal.pntd.
0000358.s002 (0.05 MB DOC)
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